Endometrial profile of tamoxifen and low-dose estradiol combination therapy.

ABSTRACT:

Purpose

Combination estrogen + progestin therapy has been associated with increased breast cancer risk in postmenopausal women. Selective estrogen receptor modulators (SERM) are potential alternatives to progestins, although the endometrial safety of estrogen + SERM co-therapies is not known. The goal of this study was to evaluate the endometrial profile of low-dose estradiol and the SERM tamoxifen alone and in combination.

Experimental design

Twenty-four postmenopausal female cynomolgus macaques were randomized by social group to receive placebo, low-dose micronized estradiol (E(2); 0.25 mg/1,800 kcal), the SERM tamoxifen (Tam; 20 mg/1,800 kcal), or E(2) + Tam for 4 months in a parallel-arm design.

Results

Tamoxifen alone resulted in overlapping but distinct effects

SUBMITTER: Wood CE 

PROVIDER: S-EPMC2818660 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature